- Home
- SSEA vs AARD Comparison
SSEA vs AARD Comparison
Compare SSEA & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$4.65
Company Overview
Basic Information| Metric | SSEA | AARD |
|---|---|---|
| Founded | 2024 | 2017 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.7M | 85.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SSEA | AARD |
|---|---|---|
| Price | $10.19 | $4.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | 11.0K | ★ 120.0K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.94 | $3.35 |
| 52 Week High | $10.29 | $17.94 |
Technical Indicators
Market Signals| Indicator | SSEA | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 59.02 | 40.70 |
| Support Level | N/A | $3.35 |
| Resistance Level | $10.29 | $6.01 |
| Average True Range (ATR) | 0.01 | 0.53 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 23.08 | 18.22 |
Price Performance
Historical Comparison SSEA
AARD
About SSEA Starry Sea Acquisition Corp Ordinary Shares
Starry Sea Acquisition Corp is a newly organized blank check company.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.